Ratih Tri Kusuma Dewi

Ratih Tri Kusuma Dewi

Auto-generated profile, based on publicly available information

Ratih Tri Kusuma Dewi

Division of Nephrology and Hypertension, Department of Internal Medicine, Universitas Sebelas Maret, Surakarta, Indonesia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Narra J
Verified
Journal Article
Open access
PDF file
FTFredo Tamara
Fredo Tamara
JFJonny Karunia Fajar
Jonny Karunia Fajar
CGCamoya Gersom
Camoya Gersom
RWRamadi S. Wicaksono
Ramadi S. Wicaksono
ATAlvira R. Tupamahu
Alvira R. Tupamahu
NSNur Samsu
Nur Samsu
Transplant renal artery stenosis (TRAS) is a serious complication of renal transplantation, with its prevalence and associated factors remaining inconclusive. The aim of this study was to assess the global prevalence and risk factors associated with TRAS incidence in renal transplant recipients. We conducted a meta-analysis by collecting data on the prevalence and factors associated with TRAS from articles in Scopus, Embase, and PubMed. The prevalence of TRAS was determined using a single-arm meta-analysis. The factors associated with TRAS were determined using Mantel-Haenszel analysis or inverse variance analysis. Out of 28,599 articles from the searches, 31 of them were included in the analysis. The global prevalence of TRAS was 6% among renal transplant recipients. Diabetes mellitus, hypertension, longer duration of dialysis before transplant, deceased donor, acute rejection, delayed graft function, longer cold ischemic time, and prolonged peak systolic velocity were associated with an increased risk of TRAS. Age, gender, peripheral artery disease (PAD) comorbidity, causes of end-stage renal disease (ESRD), previous dialysis modality, and cytomegalovirus infection were not associated with TRAS incidence. In conclusion, the global prevalence of TRAS in renal transplant recipients is relatively high, and some of the contributing factors to the development of TRAS are preventable. These findings could serve as a guideline for informing the management of TRAS in the future.

8 September 2022 in The Indonesian Biomedical Journal
Verified
Journal Article
Open access
PDF file
RDRatih Tri Kusuma Dewi
Ratih Tri Kusuma Dewi
DRDhani Redhono
Dhani Redhono
ASAgung Susanto
Agung Susanto
DPDiding Heri Prasetyo
Diding Heri Prasetyo
ENEvi Nurhayatun
Evi Nurhayatun
BPBambang Purwanto
Bambang Purwanto
BACKGROUND: Anthrax is a zoonotic disease caused by Bacillus anthracis, whose endospores stimulate the release of pro-inflammatory cytokines and promote oxidative stress. Propolis, a natural resource that can be found in Indonesia, has been proven to have anti-apoptotic and antioxidant role which might be a potential adjuvant therapy for anthrax treatment. Hence in this study we aimed to investigate effect of propolis as an anti-inflammatory, anti-apoptotic, and antioxidant in anthrax rats model by examining the level of tumor necrosis factor (TNF)-α, caspase-3, and malondialdehyde (MDA), respectively.METHODS: This was an experimental post-test only study with 40 male rats weighed 180-200 g that were induced by anthrax spores injected subcutaneously. The rats were divided into one control positive group and four intervention groups that were administered with 200 mg/kgBW propolis extract for 7 to 14 days. The levels of serum TNF-α, caspase-3, and MDA were measured using enzyme-linked immunosorbent assay (ELISA) and analyzed with bivariate analysis.RESULTS: TNF-α, caspase-3, and MDA level were found lower in anthrax rats model given ethanol extract of propolis than the control group. The lowest concentration of TNF-α value was found in group administered with propolis extract 200 mg/kgBW for 7 days before the anthrax induction (6.136±0.205 pg/mL). The results were similar to the MDA serum and caspase-3 which were the lowest when the propolis was administered 7 days earlier (1.893±0.188 nmol/mL and 2.040±0.067 ng/mL). There was significant difference in the TNF-α, caspase-3, and MDA serum levels (p≤0.001) compared to control group.CONCLUSION: Propolis has anti-apoptotic and antioxidant effects which can be used as complementary therapy in anthrax infection.KEYWORDS: propolis, anthrax, anti-apoptotic, antioxidants

1 April 2020 in Jurnal Penyakit Dalam Indonesia
Verified
Journal Article
Open access
PDF file
RDRatih Tri Kusuma Dewi
Ratih Tri Kusuma Dewi
WPWachid Putranto
Wachid Putranto
ASAgung Susanto
Agung Susanto
ASAryo Suseno
Aryo Suseno
BPBambang Purwanto
Bambang Purwanto
MSMuhammad Raditia Septian
Muhammad Raditia Septian
Hubungan Kualitas Hidup dan Status Nutrisi pada Pasien Penyakit Ginjal Kronik dengan Tipe Dialisis

29 May 2025 in BioMedicine
Verified
Journal Article
Open access
PDF file
RDRatih Tri Kusuma Dewi
Ratih Tri Kusuma Dewi
BPBambang Purwanto
Bambang Purwanto
BWBrian Wasita
Brian Wasita
VWVitri Widyaningsih
Vitri Widyaningsih
Background: Prolonged exposure of peritoneal membrane to dialysate solution is known to cause fibrosis mediated by imbalanced inflammatory response and oxidative stress. In this context, proinflammatory cytokines including TGF-β and IL-1β, along with oxidative stress markers namely SOD and MDA, present in circulation, could serve as indicators of fibrosis. This phenomenon has the potential to interfere with the optimization of Chronic Kidney Disease (CKD) treatment. Other oral antioxidant supplements have been widely studied to prevent peritoneal damage, but investigations regarding Astaxanthin (AST) effect on fibrosis marked with proinflammatory cytokine are still limited. Aims: This study aimed to investigate the protective role of AST supplementation against fibrosis in peritoneal dialysis by evaluating proinflammatory cytokine levels. Results: The results showed that AST supplementation reduced the levels of MDA, TGF-β, and IL-1β within the circulation while also improving SOD concentration in peritoneal dialysis-induced rats, as indicated by p < 0.05. Conclusion: This study found that AST supplementation might prevent peritoneal fibrosis by decreasing MDA, TGF-β, and IL-1β, as well as increasing SOD levels in serum.

23 September 2023 in Journal of Nephropathology
Verified
Journal Article
Open access
WPWachid Putranto
Wachid Putranto
GFGigih Fitriawan
Gigih Fitriawan
RDRatih Tri Kusuma Dewi
Ratih Tri Kusuma Dewi
ASAryo Suseno
Aryo Suseno
ANArief Nurudhin
Arief Nurudhin
YPYeremia Suryo Pratama
Yeremia Suryo Pratama
Introduction: Diabetic kidney disease (DKD) progression resulted in increased intrarenal oxidative stress and increased inflammatory resulting in further renal fibrosis. Achatina fulica mucus was regarded to exerts anti-oxidative and anti-inflammatory effect. Objectives: This study aims to observe the effect of administration of A. fulica mucus on oxidative stress and inflammation biomarkers in DKD-induced rats. Methods and Materials: In this study, we used 32 males white Wistar rats divided into four groups; a control, and other three different groups induced with 45 mg/kg streptozocin (STZ) and 110 mg/kg nicotinamide (NA) intra-peritoneally. Achatina fulica mucus was administered orally in the last groups; 3.5 mL/d (S1), and 7 mL/d (S2). Post-test measurement of inflammatory and oxidative biomarker was used to determine the outcome. Results: The study resulted in reduction of malondialdehyde (MDA), transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), high sensitivity C-reactive protein (hs-CRP), vascular endothelial growth factor (VEGF), and interleukin-1β (IL-1β) in A. fulica mucus administration in our STZ-NA induced rats, with higher dose of the mucus further reduce the inflammatory and oxidative stress biomarkers. Conclusion: Current study showed the potential of A. fulica mucus usage in future management of inflammation and oxidative stress in diabetes and DKD.

29 January 2024 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
RDRatih Tri Kusuma Dewi
Ratih Tri Kusuma Dewi
BPBambang Purwanto
Bambang Purwanto
BWBrian Wasita
Brian Wasita
VWVitri Widyaningsih
Vitri Widyaningsih
RCRisya Cilmiaty
Risya Cilmiaty
IPIndah Saigitaisna Putri
Indah Saigitaisna Putri
Introduction: Peritoneal dialysis (PD) is a recommended treatment for chronic kidney disease (CKD). Continuous exposure to dialysate solution in PD leads to peritoneal fibrosis, which is characterized by changes in morphology and function of the peritoneal membrane. Astaxanthin is considered to have potent antioxidant and anti-inflammatory properties, which has a promising anti-fibrosis effect and suppresses peritoneal thickness in peritoneal fibrosis. Objectives: This study aimed to investigate the impact of astaxanthin supplementation on histological features among PD model rats, which determined astaxanthin as a potential anti-fibrotic agent for PD. Materials and Methods: This study used a laboratory experimental study with a posttest-only control group design. Thirty-two male rats were divided randomly into four groups. There are two control groups and two treatment groups. Negative (NC), given intraperitoneal (IP) injection of sterilized aquadest, positive control (PC), given dialysate 4.25% injection IP. Treatment group 1 (T1) was given dialysate 4.25% injection IP and astaxanthin 0.216 mg supplementation for 14 days, and treatment group 2 (T2) was given dialysate 4.25% IP and astaxanthin 0.216 mg supplementation for 21 days. The peritoneum tissues were then collected and prepared for histological examination. Results: Astaxanthin supplementation prevents peritoneal fibrosis development in CKD model rats (P0.05). Conclusion: Astaxanthin could reduce fibrotic thickness in PD model rats. This study was relevant to conclude that astaxanthin has a potential antifibrotic agent for PD.